IL238713D0 - Self-regulated release of active pharmaceutical ingredient - Google Patents

Self-regulated release of active pharmaceutical ingredient

Info

Publication number
IL238713D0
IL238713D0 IL238713A IL23871315A IL238713D0 IL 238713 D0 IL238713 D0 IL 238713D0 IL 238713 A IL238713 A IL 238713A IL 23871315 A IL23871315 A IL 23871315A IL 238713 D0 IL238713 D0 IL 238713D0
Authority
IL
Israel
Prior art keywords
self
active pharmaceutical
pharmaceutical ingredient
regulated release
regulated
Prior art date
Application number
IL238713A
Other languages
Hebrew (he)
Original Assignee
Acura Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261731901P priority Critical
Priority to PCT/US2013/072249 priority patent/WO2014085599A1/en
Application filed by Acura Pharmaceuticals Inc filed Critical Acura Pharmaceuticals Inc
Publication of IL238713D0 publication Critical patent/IL238713D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
IL238713A 2012-11-30 2015-05-10 Self-regulated release of active pharmaceutical ingredient IL238713D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201261731901P true 2012-11-30 2012-11-30
PCT/US2013/072249 WO2014085599A1 (en) 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient

Publications (1)

Publication Number Publication Date
IL238713D0 true IL238713D0 (en) 2015-06-30

Family

ID=50826034

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238713A IL238713D0 (en) 2012-11-30 2015-05-10 Self-regulated release of active pharmaceutical ingredient

Country Status (11)

Country Link
US (5) US9101636B2 (en)
EP (2) EP3446685A1 (en)
JP (5) JP5922851B2 (en)
CN (3) CN104968333B (en)
AU (2) AU2013352162B2 (en)
CA (1) CA2892908C (en)
ES (1) ES2691982T3 (en)
IL (1) IL238713D0 (en)
MX (1) MX2015006613A (en)
RU (2) RU2018141241A (en)
WO (1) WO2014085599A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2570454T3 (en) 2003-03-26 2016-05-18 Egalet Ltd Morphine controlled release system
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
EP3446685A1 (en) * 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
CA2906915A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
EP3122336A4 (en) * 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
JP6544749B2 (en) * 2014-07-15 2019-07-17 オディディ,イサ Compositions and methods for reducing overdose
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA2955477A1 (en) * 2014-09-27 2016-03-31 Jayendrakumar Dasharathlal PATEL Pharmaceutical abuse deterrent composition
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210596A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3260646A (en) 1962-10-19 1966-07-12 Ferring Ab Medication with mechanism to prevent overdosage
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
DE2530563C2 (en) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen, De
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4389393B1 (en) 1982-03-26 1985-10-22
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4666705A (en) 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4800083A (en) * 1986-10-20 1989-01-24 R. P. Scherer Corporation Sustained release method and product
US4801461A (en) 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5114942A (en) 1989-03-31 1992-05-19 Yale University Treating habit disorders
US5059600A (en) 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5284662A (en) 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5431916A (en) 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5484606A (en) 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
WO1995033446A1 (en) 1994-06-03 1995-12-14 The Procter & Gamble Company Fast dissolving dosage forms
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5660859A (en) 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
NZ280610A (en) 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP2001527514A (en) 1996-04-10 2001-12-25 ワーナー―ランバート・カンパニー Denaturation agent for sympathomimetic amine salt
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
DK1014941T3 (en) 1996-06-26 2009-07-27 Univ Texas Extrudable pharmaceutically hot melt formulation
US6024980A (en) 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
US5919481A (en) 1996-06-28 1999-07-06 Ncneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6027746A (en) 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
WO1998053802A1 (en) 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
US6153621A (en) 1997-06-23 2000-11-28 The University Of Kentucky Research Foundation Combined antagonist compositions
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
DE19740983A1 (en) 1997-09-18 1999-04-08 Warner Lambert Co N D Ges D St Solid oral formulation based on ephedrine and similar compounds containing fats or gel forming agents and surfactants making isolation difficult
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
WO1999063970A1 (en) 1998-06-11 1999-12-16 Pharmacia & Upjohn Company Delavirdine tablet formulation
DE69928806T2 (en) 1998-07-01 2006-07-20 Warner-Lambert Co. Llc (-) - pseudoephedrine as a sympathomimetic drug
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GT199900148A (en) 1998-09-10 2001-02-28 Denaturants to sympathomimetic amines salts.
SE9803239D0 (en) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
WO2000035295A1 (en) 1998-12-15 2000-06-22 Wm. Wrigley Jr. Company Controlling release of active agents from a chewing gum coating
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030170181A1 (en) 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6613357B2 (en) 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6277409B1 (en) 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10010524C2 (en) * 2000-03-07 2002-08-29 Freudenberg Carl Kg Stripper with integrated seal
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
AU2001274585B2 (en) * 2000-06-21 2005-09-15 Otsuka Pharmaceutical Co., Ltd. Preparations for measuring gastric pH value and method of measuring gastric pH value by using the same
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20100010101A1 (en) 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
US20020022057A1 (en) 2000-08-17 2002-02-21 Battey Alyce S. Oral delivery of pharmaceuticals via encapsulation
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20020119196A1 (en) 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
US6800668B1 (en) 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US6559159B2 (en) 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
EP1240897B1 (en) 2001-03-14 2006-06-21 Pfizer Products Inc. Pharmaceutical tablet and process for making thereof
ME00330B (en) 2001-05-02 2011-05-10 Euro Celtique Sa Once-a-day oxycodone formulations
AT345112T (en) 2001-05-11 2006-12-15 Endo Pharmaceuticals Inc Opioid-containing dosage form against abuse
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
CA2447693A1 (en) 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003013481A1 (en) 2001-08-03 2003-02-20 Bakulesh Mafatlal Khamar The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
EP1429728A1 (en) 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003026743A2 (en) 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040081695A1 (en) 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
AU2002356831B2 (en) 2001-10-22 2006-06-08 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003039561A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
AU2003224419A1 (en) 2002-02-20 2003-09-09 Strides Arcolab Limited Orally administrable pharmaceutical formulation
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004002445A2 (en) 2002-06-26 2004-01-08 Cadila Healthcare Limited Novel floating dosage form
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
EP1545468A4 (en) 2002-09-20 2007-06-20 Alpharma Inc Sustained-release opioid formulations and methods of use
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
RU2333745C2 (en) 2002-10-25 2008-09-20 Лабофарм Инк. Compositions with controlled liberation
EP2186510B1 (en) 2003-03-26 2013-07-10 Egalet Ltd. Matrix compositions for controlled delivery of drug substances
BR0215923B1 (en) 2002-11-13 2013-01-22 articular facet interference screw.
US7192966B2 (en) 2002-11-15 2007-03-20 Branded Products For The Future Pharmaceutical composition
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004100857A2 (en) 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
KR20060095863A (en) 2003-08-06 2006-09-04 니르말 뮬레 Pharmaceutical composition containing water soluble drug
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Abuse-proofed dosage form
CA2535846A1 (en) 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH A process for preparing a secured against misuse dosage form
US8293799B2 (en) 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
TW201509943A (en) 2004-03-30 2015-03-16 Euro Celtique Sa Oxycodone hydrochloride composition, pharmaceutical dosage form, sustained release oral dosage form and pharmaceutically acceptable package having less than 25 PPM 14-hydroxycodeinone
DE102004020220A1 (en) 2004-04-22 2005-11-10 Grünenthal GmbH A process for preparing a secured against misuse, solid dosage form
ES2385832T3 (en) 2004-05-21 2012-08-01 Accu-Break Technologies, Inc. pharmaceutical tablets having a relatively inactive segment
JP2008500288A (en) 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー Supply system oral therapeutic compound
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH A process for preparing a secured against misuse, solid dosage form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006017159A1 (en) 2004-07-09 2006-02-16 Drugtech Corporation Controlled phase composition technology as an improved process for protection of drugs
US20060018837A1 (en) 2004-07-26 2006-01-26 Victory Pharma, Inc. Pharmaceutical compositions and methods for the prevention of drug misuse
US20060093631A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Unbreakable dosage forms with delayed release
CN101212953A (en) 2005-03-29 2008-07-02 麦克内尔-Ppc股份有限公司 Compositions with hydrophilic drugs in a hydrophobic medium
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
FR2898056B1 (en) 2006-03-01 2012-01-20 Ethypharm Sa Tablets resistant to crushing intended to prevent the illicit diversion
RU2435569C2 (en) 2006-03-16 2011-12-10 Трис Фарма, Инк. Compositions with modified release, containing complexes medication-ion-exchanging resin
WO2007113856A2 (en) 2006-03-31 2007-10-11 Rubicon Research Private Limited Directly compressible composite for orally disintegrating tablets
US20140010860A1 (en) * 2006-05-12 2014-01-09 Isa Odidi Abuse and alcohol resistant drug composition
AU2007261098A1 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient
US20080095843A1 (en) 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
EP2043613A1 (en) 2006-07-14 2009-04-08 Fmc Corporation Solid form
AU2007275033A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
EP2049548A1 (en) * 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
AU2007323018B2 (en) 2006-09-04 2011-02-03 Panacea Biotec Limited Programmable buoyant delivery technology
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
EP2155159B1 (en) 2007-05-08 2019-07-10 Hercules LLC Robust rapid disintegration tablet formulation
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2167049B1 (en) 2007-06-04 2016-08-31 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
US8420700B1 (en) 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
DK2200588T3 (en) 2007-09-25 2019-07-01 Solubest Ltd Compositions concerning lipofile active relations and method of production thereof
US20090081291A1 (en) 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
EP2205213A2 (en) 2007-10-01 2010-07-14 Laboratorios Lesvi, S.L. Orodispersible tablets
WO2009066146A2 (en) 2007-11-19 2009-05-28 Cadila Pharmaceuticals Ltd. Stable solutions of sparingly soluble actives
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
WO2009080021A1 (en) 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum tablet
EP2229156B1 (en) 2007-12-20 2016-11-09 Fertin Pharma A/S Chewing gum tablet and method of dosing pharmaceutically active ingredients in such chewing gum tablet
DK2229158T3 (en) 2007-12-20 2016-12-12 Fertin Pharma As Compressed chewing gum tablet
KR20100134557A (en) 2008-01-11 2010-12-23 씨아이피엘에이 엘티디. Solid pharmaceutical dosage form
RU2493830C2 (en) 2008-01-25 2013-09-27 Грюненталь Гмбх Drug form
BRPI0908114A2 (en) 2008-02-15 2015-10-06 Sun Pharma Advanced Res Co Ltd controlled release oral tablet
WO2010038691A1 (en) * 2008-09-30 2010-04-08 アステラス製薬株式会社 Particulate pharmaceutical composition for oral administration
RU2011119494A (en) 2008-10-14 2012-11-27 Макнейл Аб Intraoral The multicomponent dosage form of the preparation and its use
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
EP2198859A1 (en) 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release
US20100260842A1 (en) 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
AR076835A1 (en) * 2009-05-01 2011-07-13 Eurand Inc Tablet compositions comprising orally disintegrating drug combinations at high and low doses. method.
CN102573811A (en) * 2009-06-02 2012-07-11 陶氏环球技术有限责任公司 Sustained release dosage form
JP2013504562A (en) 2009-09-17 2013-02-07 カディラ・ヘルスケア・リミテッド Pharmaceutical composition for reducing alcohol-induced dose dumping
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011066980A2 (en) * 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
WO2011079074A1 (en) 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
JP5534004B2 (en) * 2010-03-29 2014-06-25 アステラス製薬株式会社 Orally disintegrating tablets
EP2635258A1 (en) * 2010-11-04 2013-09-11 AbbVie Inc. Drug formulations
EP3446685A1 (en) * 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
CA2906915A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent
DE202014010649U1 (en) * 2013-05-06 2016-02-26 Future Motion, Inc. Self-stabilizing skateboard

Also Published As

Publication number Publication date
US9320796B2 (en) 2016-04-26
CN104968333A (en) 2015-10-07
US9101636B2 (en) 2015-08-11
CN107595793A (en) 2018-01-19
JP2017036315A (en) 2017-02-16
US20140155388A1 (en) 2014-06-05
AU2018260929A1 (en) 2018-11-29
MX2015006613A (en) 2015-11-16
EP2925304B1 (en) 2018-09-05
JP2019112441A (en) 2019-07-11
JP2016166225A (en) 2016-09-15
US20170239354A1 (en) 2017-08-24
JP2018070657A (en) 2018-05-10
EP2925304A1 (en) 2015-10-07
US20180326065A1 (en) 2018-11-15
CN108743549A (en) 2018-11-06
US9662393B2 (en) 2017-05-30
CN104968333B (en) 2018-07-10
JP2016501231A (en) 2016-01-18
CA2892908A1 (en) 2014-06-05
ES2691982T3 (en) 2018-11-29
EP3446685A1 (en) 2019-02-27
JP5922851B2 (en) 2016-05-24
JP6027283B2 (en) 2016-11-16
CA2892908C (en) 2016-04-12
US20160199388A1 (en) 2016-07-14
AU2013352162B2 (en) 2018-08-16
RU2673818C2 (en) 2018-11-30
JP6272434B2 (en) 2018-01-31
AU2013352162A1 (en) 2015-05-28
WO2014085599A1 (en) 2014-06-05
RU2018141241A (en) 2019-01-24
EP2925304A4 (en) 2016-05-11
RU2015124694A (en) 2017-01-10
US20150374821A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
HK1203942A1 (en) Therapeutically active compounds and their methods of use
GB201212513D0 (en) Therapeutic agents
HK1205690A1 (en) Pharmaceutical composition and administration thereof
HK1216643A1 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical use
AP201407922A0 (en) Pharmaceutical formulations of TNF-alpha antibodies
HK1198439A1 (en) Therapeutically active compounds and their methods of use
HK1206270A1 (en) Controlled release formulations for the delivery of hif-1 inhibitors hif-1
HK1209079A1 (en) Catalytic forms and formulations
HK1211209A1 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
IL233756A (en) Hydroxamic acid derivatives and pharmaceutical compositions comprising them
EP2804850A4 (en) Therapeutically active compounds and their methods of use
HRP20150835T1 (en) Controlled release pharmaceutical dosage forms
HUE039664T2 (en) N-arylamidine-substituted trifluoroethylsulfide derivatives as acaricides and insecticides
ZA201406145B (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
SG11201405243TA (en) Inhalable pharmaceutical compositions
DK2804587T3 (en) Formulation and procedure for increasing the biodeless of pharmaceuticals
HK1212701A1 (en) Formulations of enzalutamide
IL236221A (en) Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases
EP2739144A4 (en) Compounds and therapeutic uses thereof
IL238807D0 (en) Pharmaceutical compositions
EP2891658A4 (en) Tenofovir prodrug and pharmaceutical uses thereof
IL236024A (en) Benzimidazole-proline derivatives and pharmaceutical compositions comprising them
HK1205697A1 (en) Prodrugs of hydroxyl-comprising drugs
RU2015124694A (en) Self-adjustable release of pharmaceutical ingredient
LT2854768T (en) Pharmaceutical compositions of pemetrexed

Legal Events

Date Code Title Description
FF Patent granted